AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, drug engineering, development and manufacturing, to develop second-generation bacteriophage products. Its pipeline is based on the use of bacteriophages, a family of viruses that infect only bacteria. The Company’s lead program is AmpliPhage-002, for the treatment of staphylococcus aureus (S. aureus) infections, including methicillin-resistant staphylococcus aureus (MRSA). It also has two other product candidates in development: AmpliPhage-001 for the treatment of Pseudomonas aeruginosa (P. aeruginosa) lung infections in cystic fibrosis (CF) patients and AmpliPhage-004 for the treatment of clostridium difficile (C. difficile) infections.
